Literature DB >> 10696251

An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.

J L Duque1, K R Loughlin.   

Abstract

Superficial bladder cancer accounts for approximately 70% to 80% of all newly diagnosed bladder cancers. The vast majority of these cancers are transitional bladder tumors of various histologic grades (I to III). Superficial tumors include carcinoma in situ (CIS), tumors confined to the epithelium (Ta), and superficial tumors that invade the lamina propria (T1) but do not involve superficial muscle layers. The primary treatment for eradication of stage Ta and T1 bladder cancers is transurethral resection of the tumor. Many patients with superficial bladder tumors treated with endoscopic surgery alone have recurrence or tumor progression at some point in their follow-up, and, in these patients, the need for adjuvant treatment becomes a major concern.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10696251     DOI: 10.1016/s0094-0143(05)70240-8

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  9 in total

Review 1.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Recovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment.

Authors:  Sung Hyun Kang; Russ Chess-Williams; Shailendra Anoopkumar-Dukie; Catherine McDermott
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-03       Impact factor: 3.000

3.  Cytomorphological effects of mitomycin C on urothelial cells: eosinophils may be clue to the drug-induced changes.

Authors:  Gulcin Guler Simsek; Erdem Vargol; Hulya Simsek
Journal:  Cell J       Date:  2014-10-04       Impact factor: 2.479

4.  [Prevalence of lymph node metastases in non-muscle-invasive bladder cancer. Delay of radical cystectomy and upstaging in the cystectomy specimen as risk factors].

Authors:  C Wiesner; C Thomas; A Salzer; R Gillitzer; C Hampel; J W Thüroff
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

5.  Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.

Authors:  Ralph Madeb; Dragan Golijanin; Katia Noyes; Susan Fisher; Judith J Stephenson; Stacey R Long; Joy Knopf; Gary H Lyman; Edward M Messing
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

Review 6.  Localized bladder cancer.

Authors:  J I Izawa; H B Grossman
Journal:  Curr Treat Options Oncol       Date:  2000-12

Review 7.  The health economics of bladder cancer: a comprehensive review of the published literature.

Authors:  Marc F Botteman; Chris L Pashos; Alberto Redaelli; Benjamin Laskin; Robert Hauser
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy.

Authors:  Michael A Moriarty; Matthew A Uhlman; Megan T Bing; Michael A O'Donnell; James A Brown; Chad R Tracy; Sundeep Deorah; Kenneth G Nepple; Amit Gupta
Journal:  BMC Urol       Date:  2015-05-28       Impact factor: 2.264

9.  Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer.

Authors:  Francesca Suriano; Daniele Santini; Giuseppe Perrone; Michela Amato; Bruno Vincenzi; Giuseppe Tonini; Andrea Muda; Sara Boggia; Maurizio Buscarini; Francesco Pantano
Journal:  J Exp Clin Cancer Res       Date:  2013-11-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.